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We present a case of a bisphosphonate-related femur fracture in an elderly woman, who failed treatment
with both cephalomedullary nail and proximal femoral locking plate, leading to successful treatment
with total hip arthroplasty. Hardware failure should be included in the differential of patients with
previous internal ﬁxation of bisphosphonate-related femur fracture that present with hip or groin pain.
Arthroplasty can be an acceptable salvage option in an active elderly patient with a bisphosphonate-
related femur fracture.
© 2016 The Authors. Published by Elsevier Inc. on behalf of The American Association of Hip and Knee
Surgeons. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Introduction
Bisphosphonates reduce the overall risk of fractures in patients
with osteoporosis, even after cessation of use [1]. Numerous studies
suggest a link between prolonged bisphosphonate therapy and
atypical fractures of the femur [2,3]. The consensus is that
bisphosphonate-related femur fractures (BRFFs) are rare [2,3].
There are no standardized practices for the surgical manage-
ment of BRFFs. The use of total hip arthroplasty (THA) in the
management of a bisphosphonate-related subtrochanteric femurclosed potential or pertinent
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c-nd/4.0/).fracture has not been reported in the surgical literature. We
describe such a case in an active elderly woman who failed ﬁx-
ation with a cephalomedullary nail (CMN) and proximal femoral
locking plate (PFLP) necessitating treatment with proximal femoral
replacement (PFR). The patient was informed that information
concerning her case would be submitted for publication.Case history
A 69-year-old woman treated with a CMN a month prior at an
outside hospital for a left atypical subtrochanteric femur fracture
presented to our emergency departmentwith a complaint of left hip
pain. She was on bisphosphonate therapy for the past 10 years. She
was physically active before her initial fracture. She reported a one-
day history of pain that began suddenly while attempting to get
off the toilet. The painwas localized to her left groin andwas steady,
continuous, nonradiating, exacerbated bymovement, and inhibited
ambulation. Physical examination revealed a healed operative
wound at her lateral left hip. Her left leg was held preferentially in
external rotation. Subsequent radiographs revealed an angulated
left subtrochanteric fracture with a transverse fracture line through
the lateral cortex, a shortmedial spike, and failureof theCMN(Fig.1).ciation of Hip and Knee Surgeons. This is an open access article under the CC BY-NC-
Figure 1. Anteroposterior (AP) radiograph of the left hip showing a bisphosphonate-
related femur fracture treated with a cephalomedullary nail that went on to implant
failure.
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hardware and open reduction and internal ﬁxation of her left
proximal femur. After the CMN was removed, impaction bone
grafting of the femoral head, femoral neck, and greater trochanter
was performed using allograft bone chips and demineralized bone
matrix. A laterally based PFLP was applied after compression of
the fracture (Fig. 2a and b). She was discharged 4 days later to a
skilled nursing facility with toe-touch weight-bearing precautionsFigure 2. (a) Flouroscopic view of compression being applied via a Farabeuf clamp. (b) Flouro
the left hip after treatment of the bisphosphonate-related femur fracture with compression
femur fracture treated with a proximal femoral locking plate that went on to implant failuwith calcium carbonate and vitamin D supplementation. Her
bisphosphonate therapy was discontinued.
At 2 weeks, her left hip painwas steadily decreasing, her wound
was healed, and she had no postoperative neurovascular deﬁcits.
Radiographic images revealed a stable construct and showed no
evidence of hardware failure (Fig. 2c).
At 2 months, the patient complained of increasing left hip pain
and inability to ambulate. She did not report any recent falls or
other traumatic events. A physical examination was notable for
pain with range of motion of her hip. Review of her radiographs
demonstrated an atrophic nonunion at the site of the displaced
subtrochanteric femur fracture and failure of the laterally based
PFLP just proximal to the fracture site (Fig. 2d). Erythrocyte sedi-
mentation and C-reactive protein levels were normal, so 2 surgical
options were reviewed with the patientd(1) placement of a ﬁxed
angle blade plate with compression at the fracture site, possible
addition of autologous bone graft or other biologic agent, and
initiation of teriparatide therapy or (2) THA with a distally ﬁxed
implant. The risks and beneﬁts of each intervention were outlined,
including the off label use of teriparatide to act as an anabolic agent
and make bone as well as the theoretical risk of osteosarcoma.
The patient, in concert with her family and surgeon, selected THA.
The next morning, she underwent removal of hardware and
reconstruction of the left hip via a posterior approach. A large
amount of the proximal femur necessitated resection as it was
deemed intraoperatively to be nonviable. Once the nonunion was
resected back to healthy bone, a PFR was required for reconstruc-
tion of the left hip (Fig. 3a). Intraoperative range of motion at the
hip joint was observed to be stable. The remainder of the patient’s
hospitalization was uneventful. She was able to ambulate with
physical therapy on postoperative day 1 and was subsequently
discharged to a skilled nursing facility for further rehabilitation
with left-sided posterior hip precautions and touch down weight-
bearing restrictions.
At 6 weeks, she reported good pain control on occasional
oral narcotic pain medication. Her incision was healed. She was
routinely ambulating over 300 feet with a front-wheel walker.
She was advanced to weight bearing at tolerated and instructed to
beginweaning her assistive device. At 3 months, she reported good
pain control off oral narcotic pain medication and was ambulating
over 300 feet with a cane. At 2 years, she reported no pain, however,
still required a cane (Fig. 3b). Her Harris hip score had improved
dramatically from 20 preoperatively to 80 at ﬁnal follow-up.scopic view after application of the proximal femoral locking plate. (c) AP radiograph of
and a proximal femoral locking plate. (d) AP radiograph of a bisphosphonate-related
re.
Figure 3. (a) Postoperative anteroposterior radiograph of the bisphosphonate-related femur fracture treated with proximal femoral replacement and hook plate. (b)
Anteroposterior radiograph of the left hip 2 years postoperatively demonstrating no subsidence, no pedestal, and lack of greater trochanteric migration all suggestive of stable a
stable implant as well as union of the greater trochanter. (c) Frog leg lateral radiograph of the left hip 2 years postoperatively demonstrating distal spot welding, streaming
trabeculae, and fracture union all suggestive of stable osseointegration.
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Biphosphonatesareused inthe treatmentofavarietyof conditions
including primary andmetastatic tumors, heritable pediatric skeletal
disorders, and metabolic diseases of bone. The implications of long-
term bisphosphonate use are an area of ongoing research.
Bisphosphonates accumulate at the site of bone resorption and
are preferentially taken up by osteoclasts, inhibiting their ability to
effectively resorb bone by dismantling the rufﬂed boarder and
inducing apoptosis [4]. Bisphosphonates reduce bone turnover,
increase overall mineralization, and affect the organic matrix by
altering collagen maturity, crosslinking, and heterogeneity [2,5].
Bisphosphonates decrease cortical bone toughness [2,6].
Bone resorption by osteoclasts and bone formation by osteo-
blasts are closely linked at bone remodeling sites. Normally occur-
ring microcracks are repaired through remodeling. Excessive bone
remodeling results in bone loss and increased susceptibility
to fragility fractures. The suppression of osteoclast activity by
bisphosphonates signiﬁcantly reduces the loss of bone that occurs
through remodeling. However, this is also associatedwith increased
microdamage accumulation because microcracks are not removed
efﬁciently [7]. It is believed that microcracks accumulated and are
propagated as stress fractures resulting in an atypical fracture.
BRFFs are observed in the subtrochanteric and diaphyseal re-
gions as a result of minimal or no trauma. There can be prodromal
thigh or groin pain. The fracture may be complete, seen as a
transverse, or slightly oblique fracture extending across the entire
femoral shaft, or incomplete, manifested by a radiolucent line in the
lateral cortex and an oblique fracture line medially. They initially
appear as thickening of the lateral cortex that subsequently de-
velops into a fracture. Our patient has several of the major and
minor features of BRFFs as deﬁned by the American Society for
Bone andMineral Research and noted in numerous case reports [2].
Stress fractures heal via a different mechanism than acute
fractures.Acute fractureshealvia endochondral ossiﬁcation,marked
by cartilaginous callus formation after an initial inﬂammatory
response. Bisphosphonates do not affect the initial development ofproliferative callus; however, bisphosphonates slow the remodeling
of calciﬁed callus into mature bone [8]. On the other hand, stress
fractures heal via osteoclast-dependent bone remodeling which, as
previously discussed, is reduced by bisphosphonate treatment.
Intramedullary nailing allows for endochondral repair at the frac-
ture site,whereas compressionplatingprecludes this. Consequently,
intramedullary nailing is recognized as the preferred method of
treatment for BRFFs, even in the absence of controlled studies
evaluating surgical treatment strategies [2].
BRFFs are difﬁcult to manage surgically and hard to heal biolog-
ically [2,9-11]. In a retrospective review of 20 patients with sub-
trochanteric femur fractures, 3 of 12 (25%) patients treated with
alendronate therapy had a nonunion fracture, versus only 1 of 8
(12.5%) in patients in the control group [9]. Two of the 3 nonunions
were initially plated but required revision surgery to an intra-
medullary nail. The third nonunionwas initially treatedwith a CMN.
Based on this experience, treating BRFFs with an intramedullary
implant, cessation of the bisphosphonate, and consideration of
treatment with teraparatide postoperatively are recommended.
Another retrospective review of 25 patients with BRFFs demon-
stratedpostoperative failure of plating in3of10 (30%)plated femurs,
compared to 0 in of 15 (0%) patients treated with a nail [11].
Furthermore, none of the 20 control patients with similar, but
non-bisphosphonate-related fractures, had postoperative failure. In
addition, the time to union in the bisphosphonate cohort was 26
weeks as opposed to 19 weeks in the control cohort [11]. A case
report describes 2 BRFFs initially treated with intramedullary nails
that went on to develop atrophic nonunions. These patients were
successfully treatedwith removal of thenail anddeﬁnitive plating to
achieve compression across the fracture [10]. Another retrospective
review of 15 patients with BRFFs showed a revision rate of 46% after
nailing, with one patient receiving a blade plate [12]. These reports
collectively support the notion that BRFFs may have a higher
propensity for delayed healing and hardware failure, especially
when plate ﬁxation is used initially.
There is emerging data that bisphosphonate use during THA
may half the risk of all-cause revision and aseptic loosening
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patients on a bisphosphonate [13]. However, these data do not
speciﬁcally address the optimal type of ﬁxation for femoral of
acetabular implants, especially in the setting of a BRFF. Cementa-
tion given the osteoporotic bone is also a reasonable means of
ﬁxation in osteoporotic bone.
Summary
The standard treatment for BRFF is internal ﬁxation. However,
when ﬁxation failure occurs in a patient with osteoporotic bone a
salvage procedure with a PFR is a surgical option. THA is a possible
alternative to internal ﬁxation and hemiarthroplasty for an elderly
patient with higher functional demands and a long-life expectancy
[14,15]. THA is an acceptable treatment solution for failed internal
ﬁxation of intertrochanteric or subtrochanteric femur fractures in
the elderly [16]. In this case report, arthroplasty offered advantages
to repeat open reduction and compression with an angled blade
plate after careful consideration of patient comorbidities, func-
tional demands, and risk for revision. The degree of osteoporosis
suggested that PFR might offer a better outcome than internal
ﬁxation through bone that was signiﬁcantly nonviable in the
proximal femoral region. In addition, THA offers the advantage of
early weight bearing and mobilization, making it a potentially less
morbid option in the elderly. Moreover, the likelihood of a future
operation for a nonunion, malunion, or hardware failure is miti-
gated. This is especially important given the propensity for delayed
healing in BRFFs.References
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